Journal
ACTA NEUROLOGICA SCANDINAVICA
Volume 118, Issue 6, Pages 362-366Publisher
WILEY-BLACKWELL
DOI: 10.1111/j.1600-0404.2008.01039.x
Keywords
erythropoietin; stroke; neuroprotection; carbamylated erythropoietin; asialic erythropoietin
Categories
Ask authors/readers for more resources
Recombinant human erythropoietin was produced soon after the discovery of the erythropoietin gene in 1985 and since then, it is used in various clinical conditions such as chronic renal failure. Moreover, experimental studies have shown that erythropoietin exerts neuroprotective action as well. Recently, a clinical trial yielded promising results concerning the use of erythropoietin in stroke management. In this review, we summarize the main data which suggest that recombinant human erythropoietin and its analogues may indeed have a role in stroke treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available